Delilah Alvarado's profile photo

Delilah Alvarado

Texas

Staff Reporter at BioPharma Dive

Writer for @Biopharmadive. Girl with the dragon tattoo. Chicana. Words in @Prismreports, @wearemitu, @YRMedia, @BuiltIn. https://t.co/H1FtFYMFA7

Featured in: Favicon industrydive.com Favicon healthcaredive.com Favicon newsbreak.com Favicon builtinchicago.org Favicon wearemitu.com Favicon biopharmadive.com Favicon yr.media Favicon universitystar.com Favicon medtechdive.com Favicon builtinla.com

Articles

  • Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO

    3 weeks ago | biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo

    New drugs, however heralded, take time to embed into clinical care. Enhertu, the powerful antibody-drug conjugate from Daiichi Sankyo and AstraZeneca, was first approved in the U.S. in 2019, before the world had even heard of a novel coronavirus.

  • Bayer drug could ease side effects of common breast cancer treatment, detailed data show

    3 weeks ago | biopharmadive.com | Delilah Alvarado

    An experimental, non-hormonal drug from Bayer can reduce the hot flashes and other menopausal side effects many women taking a common breast cancer therapy experience, according to results from a late-stage clinical trial run by the pharmaceutical company. The study, known as Oasis-4, is the fourth successful trial test of Bayer’s drug, called elinzanetant.

  • Bayer drug could ease side effects of common breast cancer treatment, detailed data show

    3 weeks ago | yahoo.com | Delilah Alvarado

    This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. An experimental, non-hormonal drug from Bayer can reduce the hot flashes and other menopausal side effects many women taking a common breast cancer therapy experience, according to results from a late-stage clinical trial run by the pharmaceutical company.

  • Bispecific competition, debating oral SERDs and a bold GLP-1 prediction

    3 weeks ago | biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo

    CHICAGO — The American Society of Clinical Oncology’s annual meeting is a forum for data. On Monday, it was also the backdrop to oncology’s latest deal, when Bristol Myers Squibb and BioNTech announced a multibillion-dollar alliance around a newly in-vogue drug. BioNTech’s drug is a bispecific antibody that simultaneously targets the proteins PD-L1 and VEGF.

  • FDA clears Moderna’s new COVID vaccine, but with limits

    4 weeks ago | biopharmadive.com | Delilah Alvarado

    The Food and Drug Administration has granted an approval to Moderna’s next-generation COVID-19 vaccine, but with limits that will restrict use to older adults and people with preexisting health conditions. The OK is the first since agency leadership rolled out new guidelines for COVID shot approvals.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
350
Tweets
8K
DMs Open
Yes
Delilah Alvarado
Delilah Alvarado @Lilah_Alvarado
18 Jun 25

RT @BioPharmaDive: FDA approves twice-yearly shot of Gilead drug for HIV prevention https://t.co/nSI2d699wa $GILD by @Lilah_Alvarado

Delilah Alvarado
Delilah Alvarado @Lilah_Alvarado
2 Jun 25

RT @BentheFidler: Latest from #ASCO25: Bispecific competition, debating oral SERDs and a bold GLP-1 prediction https://t.co/emShB3dEPJ by @…

Delilah Alvarado
Delilah Alvarado @Lilah_Alvarado
27 May 25

RT @BioPharmaDive: FDA sets COVID vaccine formula as RFK Jr. narrows guidance for shots https://t.co/S0TKonWtgA $PFE $MRNA $NVAX by @Lilah_…